ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
41.02
0.00%
US Tech 100
21,141.20
-0.26%
S&P 500
6,084.19
0.82%
US Dollar vs CAD
1.4146
-0.03%
Bitcoin
100,340.91
-0.84%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Oric Pharmaceuticals Inc (ORIC) Share Price

Oric Pharmaceuticals Inc

Oric Pharmaceuticals Inc (ORIC)

NASDAQ
8.96
-0.06
(-0.67%)
Closed December 11 3:00PM
Delayed by 15 minutes
8.96
0.00
( 0.00% )
Pre Market: 3:05AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
8.96
Bid
3.59
Ask
10.60
Volume
-
0.00 Day's Range 0.00
6.33 52 Week Range 16.65
Market Cap
632.28M
Previous Close
8.96
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
420,837
Shares Outstanding
70,566,950
Dividend Yield
-
PE Ratio
-6.28
Earnings Per Share (EPS)
-1.43
Revenue
-
Net Profit
-100.7M

About Oric Pharmaceuticals Inc

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.oricpharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was US$8.96. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of US$ 6.33 to US$ 16.65.

Oric Pharmaceuticals currently has 70,566,950 shares outstanding. The market capitalization of Oric Pharmaceuticals is US$632.28 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.28.

Ask ADVFN Intelligence (AI)

ORIC Latest News

More News

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

November 25 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference...

November 12 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 08 2024
Edgar (US Regulatory)

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

November 04 2024
GlobeNewswire Inc.

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

November 01 2024
GlobeNewswire Inc.

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

October 23 2024
GlobeNewswire Inc.

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

October 09 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.775-7.960965588089.73510.218.9352100729.31685111CS
4-1.205-11.85440236110.16510.618.1053347879.25862285CS
12-2.16-19.424460431711.1212.838.1054208379.68902617CS
260.627.434052757798.3412.836.334924759.34257439CS
520.333.823870220168.6316.656.3349180110.19546281CS
156-5.69-38.839590443714.6517.262.364429947.47800599CS
260-17.04-65.53846153852640.812.3636741011.5288755CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PALIPalisade Bio Inc
US$ 3.08
(120.00%)
10.4M
DBVTDBV Technologies SA
US$ 4.39
(33.43%)
2.53M
AMPGAmplitech Group Inc
US$ 2.42
(25.39%)
10.42M
WHLRWheeler Real Estate Investment Trust Inc
US$ 5.55
(24.44%)
1.07M
ABVEAbove Food Ingredients Inc
US$ 0.6147
(22.87%)
537
KROSKeros Therapeutics Inc
US$ 19.52
(-71.57%)
35.23k
PNBKPatriot National Bancorp Inc
US$ 1.08
(-58.78%)
13
SPGCSacks Parente Golf Inc
US$ 0.60
(-57.14%)
46.33k
AVGRAvinger Inc
US$ 0.50
(-39.02%)
37.26k
HEPAHepion Pharmaceuticals Inc
US$ 0.36
(-38.46%)
1
AMPGAmplitech Group Inc
US$ 2.42
(25.39%)
10.42M
PALIPalisade Bio Inc
US$ 3.08
(120.00%)
10.41M
RGTIRigetti Computing Inc
US$ 6.68
(-9.49%)
3.21M
RZLVRezolve AI Ltd
US$ 2.145
(7.79%)
3.02M
SVMHSRIVARU Holding Ltd
US$ 0.028
(2.19%)
2.74M

ORIC Discussion

View Posts
Monksdream Monksdream 3 months ago
ORIC under $10
👍️0
Monksdream Monksdream 5 months ago
ORIC under $10
👍️0
Monksdream Monksdream 5 months ago
ORIC under $10
👍️0
Monksdream Monksdream 7 months ago
ORIC 10Q due 5/6
👍️0
Monksdream Monksdream 7 months ago
ORIC under $10
👍️0
Monksdream Monksdream 9 months ago
ORIC 10Q due 3/16
👍️0
Monksdream Monksdream 9 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 9 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 9 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 10 months ago
ORIC new 52 weewk high
👍️0
Monksdream Monksdream 11 months ago
ORIC new 52 week high
👍️0
TheFinalCD TheFinalCD 2 years ago
$ORIC LOOKS LIKE $6 COMING
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC: Tapped $5.40....... still got steam

It ain't over yet





GO $ORIC
👍️0
DH112 DH112 2 years ago
Today is green fields
👍️0
TheFinalCD TheFinalCD 2 years ago
Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a total of $25 million. The companies plan to move the treatment into a Phase 2 clinical trial in combination with elranatamab, Pfizer's investigational treatment of multiple myeloma

https://finance.yahoo.com/news/oric-pharmaceuticals-announces-clinical-development-224800151.html
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC: 5.25 now........................... lets get to $10

I know you can do it babyyyyyyyyyyyyyyyyy


GO $ORIC
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC : Now at 4.90

YESsssssssssssssss............ this is very impressive news with deal with Pfizer.

Me likes it


GO $ORIC
👍️0
crudeoil24 crudeoil24 2 years ago
Shares of Oric Pharmaceuticals Inc. jumped nearly 60% to $4.79 in premarket trading Thursday after the company agreed to sell $25 million in shares to Pfizer Inc.

The clinical-stage oncology company said Wednesday evening that Pfizer has agreed to buy nearly 5.4 million shares of Oric's common stock for $4.65 apiece.

The investment is part of a clinical development collaboration between the two companies on a Phase 2 study examining Oric's ORIC-533 treatment for multiple myeloma, the companies said.

The companies said the collaboration would potentially advance the treatment into a combination study with Pfizer's elranatamab, an investigational treatment for multiple myeloma.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

December 22, 2022 07:25 ET (12:25 GMT)
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC: BOOOoommmmmmm........... Pfiizer invests $25Milly in ORIC

Letssssssss goooooooooooooooooo.


Added 5k shares here at 4.30

Great NEWS


https://www.tipranks.com/news/oric-pharmaceuticals-nasdaqoric-stock-spikes-on-pfizer-deal

GO $ORIC
👍️0

Your Recent History

NASDAQ
ORIC
Oric Pharmaceuticals
TG
N4G
Naga
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved